Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy

• Published in: International journal of molecular sciences Vol. 23; no. 17; p. 10068
• Main Authors: Chaudhuri, Aiswarya, Kumar, Dulla Naveen, Shaik, Rasheed A., Eid, Basma G., Abdel-Naim, Ashraf B., Md, Shadab, Ahmad, Aftab, Agrawal, Ashish Kumar
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 03.09.2022; MDPI
• Subjects: Bioavailability; Blood vessels; Bone marrow; Breast cancer; Cancer therapies; Chemotherapy; Drug delivery systems; Drug resistance; Fatty acids; Lipids; Lymphatic system; Medical research; Metabolism; Metastasis; Nanoparticles; Nanotechnology; Polyethylene glycol; Review; Surfactants; Triglycerides; Womens health
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms231710068

Triple-negative breast cancer is considered the most aggressive type of breast cancer among women and the lack of expressed receptors has made treatment options substantially limited. Recently, various types of nanoparticles have emerged as a therapeutic option against TNBC, to elevate the therapeutic efficacy of the existing chemotherapeutics. Among the various nanoparticles, lipid-based nanoparticles (LNPs) viz. liposomes, nanoemulsions, solid lipid nanoparticles, nanostructured lipid nanocarriers, and lipid–polymer hybrid nanoparticles are developed for cancer treatment which is well confirmed and documented. LNPs include various therapeutic advantages as compared to conventional therapy and other nanoparticles, including increased loading capacity, enhanced temporal and thermal stability, decreased therapeutic dose and associated toxicity, and limited drug resistance. In addition to these, LNPs overcome physiological barriers which provide increased accumulation of therapeutics at the target site. Extensive efforts by the scientific community could make some of the liposomal formulations the clinical reality; however, the relatively high cost, problems in scaling up the formulations, and delivery in a more targetable fashion are some of the major issues that need to be addressed. In the present review, we have compiled the state of the art about different types of LNPs with the latest advances reported for the treatment of TNBC in recent years, along with their clinical status and toxicity in detail.